Please assess the completion status of the following clinical trial:

Trial Title: Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be of non-childbearing potential~* Body mass index (BMI) ≥32.0 kg/m\^2~* In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests~* No clinically significant abnormality on electrocardiogram~* Has documented hepatic fat content ≥10% within 6 months of enrollment~* Maintained stable weight (by history) for at least 4 weeks~* Agrees not to initiate a weight loss program and agrees to maintain consistent dietary habits and exercise routines for the duration of the study~* Has a rating of 'moderate' or 'severe' steatosis on ultrasound at the prestudy (screening) visit~Exclusion Criteria:~* Change in weight greater than 4% between prestudy visit and randomization into the study~* History of any illness that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant~* Liver disease other than fatty liver or non-alcoholic steatohepatitis (NASH)~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3x the upper limit of normal range~* Serum triglyceride level \>600 mg/dL~* History of stroke, chronic seizures, or major neurological disorder~* History of clinically significant endocrine, gastrointestinal, cardiovascular (including congestive heart failure), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases~* Had abdominal surgery, gastric bypass, bowel resection, recent liver biopsy, or any other procedure within a minimum of 4 weeks~* History of neoplastic disease~* Claustrophobia or other contraindication to magnetic resonance imaging (MRI)~* Have not washed off agents associated with changes in hepatic fat or used for treatment of Non-alcoholic fatty liver disease (NAFLD) or NASH for a minimum of 3 months prior~* Consumes excessive amounts of alcohol, coffee, tea, cola, or other caffeinated beverages~* Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) or participated in another investigational study within 4 weeks~* Significant multiple and/or severe allergies~* Intolerance or hypersensitivity to pioglitazone hydrochloride or any inactive ingredients~* Regular user of any illicit drugs or has a history of drug (including alcohol) abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- MK-4074 (Type: EXPERIMENTAL): Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
- Placebo for MK-4074 (Type: PLACEBO_COMPARATOR): Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
- Pioglitazone (Type: EXPERIMENTAL): Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
- Placebo for pioglitazone (Type: PLACEBO_COMPARATOR): Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete